Drug Safety Evaluation, Drug Developmental Research Laboratories, Shionogi & Co., Ltd., Toyonaka, Japan.
Toxicology. 2013 Jan 7;303:169-76. doi: 10.1016/j.tox.2012.11.008. Epub 2012 Nov 23.
Recent efforts have been made to identify useful urinary biomarkers of nephrotoxicity. Furthermore, the application of urine to the other toxicities as new biomarker source has been recently expanded. Meanwhile, correction of urinary biomarker concentrations according to fluctuations in urine flow rate is required for adequate interpretation of the alteration. The urinary biomarker-to-creatinine ratio (UBCR) is widely used because of the convenience, while the urinary biomarker-excretion rate is regarded as the gold standard corrective method. Because creatinine is a catabolite in energy production in muscles, we hypothesized that altered muscle mass could affect creatinine kinetics, ultimately affecting UBCR. However, no study has examined this hypothesis. In this study, we examined the influence of muscle mass gain on UBCR, using male Sprague-Dawley rats during the growth phase, 6-12-week old. Both plasma creatinine and excretion of urinary creatinine (Ucr excretion) showed increases with muscle mass gain in rats, in which the alterations of UBCR were lowered. The renal mRNA level of the organic cation transporter-2 (Oct2), a creatinine transporter, showed an age-related increase, whereas the mRNA level of multidrug and toxin extrusions-1 (Mate1) remained constant. Multiple regression analysis showed that the increase in creatinine clearance highly contributed to the age-related increase in Ucr excretion compared to the mRNA levels of Oct2 and Mate1. This suggested that the age-related increase in Ucr excretion may be attributable to the increased transglomerular passage of creatinine. In conclusion, the results suggest that muscle mass gain can affect creatinine kinetics, leading to underestimation of UBCR. Therefore, it is important to understand the characteristics of the corrective method when using urinary biomarker, the failure of which can result in an incorrect diagnosis.
最近已经做出了努力来识别有用的肾毒性的尿生物标志物。此外,尿液作为新的生物标志物来源在其他毒性方面的应用最近也得到了扩展。同时,需要根据尿液流量的波动来校正尿生物标志物的浓度,以充分解释其变化。由于方便,尿生物标志物与肌酐的比值(UBCR)被广泛应用,而尿生物标志物排泄率被认为是校正的金标准方法。因为肌酐是肌肉中能量产生的代谢产物,我们假设肌肉质量的改变可能会影响肌酐的动力学,最终影响 UBCR。然而,还没有研究检验过这个假设。在这项研究中,我们使用雄性 Sprague-Dawley 大鼠在生长阶段(6-12 周龄),检验了肌肉质量增加对 UBCR 的影响。在大鼠中,血浆肌酐和尿肌酐排泄(Ucr 排泄)都随着肌肉质量的增加而增加,而 UBCR 的改变则降低。有机阳离子转运体-2(Oct2),一种肌酐转运体的肾 mRNA 水平表现出与年龄相关的增加,而多药和毒素外排-1(Mate1)的 mRNA 水平保持不变。多元回归分析显示,肌酐清除率的增加对 Ucr 排泄的年龄相关性增加的贡献高于 Oct2 和 Mate1 的 mRNA 水平。这表明 Ucr 排泄的年龄相关性增加可能归因于肌酐的跨肾小球传递增加。总之,结果表明肌肉质量的增加会影响肌酐的动力学,导致 UBCR 的低估。因此,当使用尿生物标志物时,了解校正方法的特点很重要,否则可能会导致错误的诊断。